Table 1.
Baseline patients' characteristics of the selected studies (n = 12)
| References | Patient’s characteristics | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients | Age (years) | Sex | Types of diabetes | Diabetes duration (months) | Dialysis duration (months) | |||
| Male | Female | |||||||
| Gai et al. [24] | 12 | 62 ± 14 | 9 (75%) | 3 (25%) | II | 39.6 (1.9−125.4) | 21.2 (2.2−41.7) | |
| Jin et al. [31] | ESDKD | 36 | 62 ± 13 | 29 (79%) | 7 (21%) | II | 156 ± 84 | / |
| ESKD | 10 | 65 ± 13 | 8 (80%) | 2 (20%) | / | 0 ± 0 | / | |
| Jung et al. [33] | 9 | 67 ± 9 | / | / | II | 288 ± 108 | / | |
| Képénékian et al. [29] | 27 | 66 ± 9 | 9 (32%) | 19 (68%) | II | 273 ± 117 | 43 ± 30 | |
| Chantrel et al. [29] | 33 | 66 ± 8 | 19 (58%) | 14 (42%) | II | 276 ± 132 | 46 ± 31 | |
| Mirani et al. [36] | 12 | 62 ± 10 | 7 (58%) | 5 (42%) | II | 180 ± 96 | 27.6 ± 15.6 | |
| Riveline et al. [38] | ESDKD | 19 | 64 ± 10 | 8 (42%) | 11 (58%) | II | 252 ± 132 | 24 (13−35) |
| Non-HD | 39 | 65 ± 6 | 25 (64%) | 14 (36%) | / | 204 ± 84 | / | |
| Kazempour-Ardebili et al. [34] | 17 | 61 ± 9 | 13 (76%) | 4 (23%) | II | 225 ± 91 | 48 ± 31.2 | |
| Divani et al. [30] | 37 | 62 ± 17 | 20 (54%) | 17 (46%) | / | / | 37.0 ± 16.9 | |
| Mori et al. [37] | 1 | 68 | 1 (100%) | 0 (0%) | / | 492 | 216 | |
| Joubert et al. [32] | 15 | 61 ± 15 | 8 (53%) | 7 (47%) | I and II | 230 ± 91.2 | 78 ± 83 | |
| Yajima T et al. [39] | 13 | 63.5 ± 11.3 | 11 (85%) | 2 (15%) | II | / | 7.3 (4.3−28.4) | |
ESDKD end-stage diabetic kidney disease, ESKD end-stage kidney disease